Hansoh Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Hansoh Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 3.5% ve 7% oranında artacağı tahmin edilmektedir. EPS'nin azalması beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

3.5%

Kazanç büyüme oranı

-3.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.1%
Gelir büyüme oranı	7.0%
Gelecekteki özkaynak getirisi	12.6%
Analist kapsamı	Good
Son güncelleme	20 Dec 2024

Gelecekteki son büyüme güncellemeleri

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01

Recent updates

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 41% Above Its Share Price

Dec 10

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Nov 21

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Nov 04

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Aug 28

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16

Kazanç ve Gelir Büyüme Tahminleri

SEHK:3692 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	13,778	4,427	4,470	4,327	17
12/31/2025	12,422	3,969	3,856	4,035	20
12/31/2024	12,069	4,132	3,563	3,320	20
6/30/2024	12,098	4,714	4,137	4,653	N/A
3/31/2024	11,101	3,996	3,446	3,885	N/A
12/31/2023	10,104	3,278	2,754	3,116	N/A
9/30/2023	9,782	2,926	2,292	2,615	N/A
6/30/2023	9,459	2,575	1,830	2,114	N/A
3/31/2023	9,421	2,579	2,140	2,427	N/A
12/31/2022	9,382	2,584	2,449	2,741	N/A
9/30/2022	9,675	2,652	2,646	3,004	N/A
6/30/2022	9,968	2,720	2,842	3,267	N/A
3/31/2022	9,952	2,717	2,472	2,922	N/A
12/31/2021	9,935	2,713	2,102	2,577	N/A
9/30/2021	9,524	2,675	1,415	2,345	N/A
6/30/2021	9,112	2,638	729	2,113	N/A
3/31/2021	8,901	2,603	840	2,252	N/A
12/31/2020	8,690	2,569	951	2,390	N/A
9/30/2020	8,377	2,526	1,775	2,802	N/A
6/30/2020	8,063	2,483	2,600	3,213	N/A
3/31/2020	8,373	2,520	2,666	3,271	N/A
12/31/2019	8,683	2,557	2,732	3,330	N/A
9/30/2019	8,615	2,357	2,529	3,092	N/A
6/30/2019	8,548	2,157	2,325	2,854	N/A
3/31/2019	8,135	2,030	2,008	2,463	N/A
12/31/2018	7,722	1,903	1,690	2,072	N/A
12/31/2017	6,186	1,595	N/A	1,402	N/A
12/31/2016	5,433	1,476	N/A	1,247	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 3692 'nin tahmini kazanç büyümesi (yıllık 3.5% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 3692 şirketinin kazançlarının (yıllık 3.5% ) Hong Kong pazarından (yıllık 11.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 3692 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 3692 şirketinin gelirinin (yıllık 7% ) Hong Kong pazarından (yıllık 7.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 3692 şirketinin gelirinin (yıllık 7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 3692 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/20 02:34
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Hansoh Pharmaceutical Group Company Limited 32 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Sharon Shi	BOCI Research Ltd.
Bo Li	BofA Global Research
Jin Zhang	China International Capital Corporation Limited

Hansoh Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 10%

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Consensus EPS estimates increase by 16%

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 14%

Recent updates

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 41% Above Its Share Price

Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

Consensus EPS estimates increase by 10%

First half dividend of HK$0.20 announced

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Now 22% undervalued

Now 24% undervalued

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Now 21% undervalued

Upcoming dividend of HK$0.14 per share

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Now 21% undervalued

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Full year 2023 earnings: EPS exceeds analyst expectations

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Consensus EPS estimates increase by 16%

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS exceeds analyst expectations

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Consensus EPS estimates fall by 12%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Executive Director exercised options to buy HK$1.1m worth of stock.

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.8% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Executive Director exercised options to buy HK$5.9m worth of stock.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week